{
    "ticker": "JSPR",
    "name": "Jasper Therapeutics, Inc.",
    "description": "Jasper Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with hematological malignancies and other serious diseases. Founded in 2020, Jasper is dedicated to transforming the treatment landscape through its pioneering approach to hematopoietic stem cell transplantation and gene therapy. The company\u2019s lead product candidate, JSP191, is a monoclonal antibody designed to selectively target and deplete hematopoietic stem and progenitor cells, facilitating safer and more effective transplants. By leveraging its proprietary technologies, Jasper aims to improve patient outcomes while addressing the significant unmet medical needs in the field of cellular therapies. With a strong commitment to advancing scientific research and patient care, Jasper is poised to make a significant impact in the realm of regenerative medicine. The company is also exploring additional therapeutic areas, including autoimmune diseases and genetic disorders, with the goal of bringing transformative treatments to patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2020",
    "website": "https://www.jaspertherapeutics.com",
    "ceo": "William J. H. Lee",
    "social_media": {
        "twitter": "https://twitter.com/JasperThera",
        "linkedin": "https://www.linkedin.com/company/jasper-therapeutics/"
    },
    "investor_relations": "https://investors.jaspertherapeutics.com",
    "key_executives": [
        {
            "name": "William J. H. Lee",
            "position": "CEO"
        },
        {
            "name": "Robert A. M. H. K. S. K. Lee",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "JSP191"
            ]
        }
    ],
    "seo": {
        "meta_title": "Jasper Therapeutics, Inc. | Innovative Therapies for Serious Diseases",
        "meta_description": "Learn about Jasper Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for hematological malignancies and other serious diseases. Explore our lead product JSP191 and our commitment to advancing regenerative medicine.",
        "keywords": [
            "Jasper Therapeutics",
            "Biotechnology",
            "JSP191",
            "Hematological Malignancies",
            "Cellular Therapies",
            "Stem Cell Transplantation"
        ]
    },
    "faq": [
        {
            "question": "What is Jasper Therapeutics known for?",
            "answer": "Jasper Therapeutics is known for developing innovative therapies, particularly targeting hematological malignancies with its lead product JSP191."
        },
        {
            "question": "Who is the CEO of Jasper Therapeutics?",
            "answer": "William J. H. Lee is the CEO of Jasper Therapeutics, Inc."
        },
        {
            "question": "Where is Jasper Therapeutics headquartered?",
            "answer": "Jasper Therapeutics is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What is the main product of Jasper Therapeutics?",
            "answer": "The main product of Jasper Therapeutics is JSP191, a monoclonal antibody aimed at improving stem cell transplantation outcomes."
        },
        {
            "question": "When was Jasper Therapeutics founded?",
            "answer": "Jasper Therapeutics was founded in 2020."
        }
    ],
    "competitors": [
        "CRSP",
        "BLUE",
        "SGEN",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}